biotech

Why Ocular Therapeutix Fell Short in Its Glaucoma Study

Posted: May 21, 2019 at 1:40 pm

Ocular Therapeutix Inc. (NASDAQ: OCUL) shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from ...
Read Full Story »

Why BioCryst’s HAE Treatment Failed to Impress

Posted: May 21, 2019 at 10:10 am

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema (HAE) patients. Specifically, the firm announced ...
Read Full Story »

Thursday’s Top 4 ASCO Movers

Posted: May 16, 2019 at 4:03 pm

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Can Danaher Walk Away From the Buyout of GE’s Biopharma Unit?

Posted: May 16, 2019 at 2:10 pm

If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric Co. (NYSE: GE). A new CEO has ...
Read Full Story »

Solid Breast Cancer Results From MacroGenics Ahead of ASCO

Posted: May 16, 2019 at 11:35 am

Looking ahead to the week of May 31 to June 4, one of the biggest health care conferences of the year, the 55th Annual Meeting of the American Society of ...
Read Full Story »

Iovance Bio’s Big Break in Cervical Cancer Ahead of ASCO

Posted: May 16, 2019 at 9:55 am

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Why There May Be a Big Issue With This Duchenne Muscular Dystrophy Study

Posted: May 14, 2019 at 1:25 pm

Duchenne muscular dystrophy (DMD) is an inherited disorder of progressive muscular weakness, especially in boys. It affects one out of 3,500 to 5,000 males worldwide and is one of the ...
Read Full Story »

The Best Biotech ETFs to Buy Ahead of ASCO

Posted: May 14, 2019 at 9:38 am

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference ...
Read Full Story »

Short Sellers Back Off Major Biotechs

Posted: May 10, 2019 at 8:55 am

The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Posted: May 9, 2019 at 2:10 pm

It may seem like a time of uncertainty for companies producing drugs if they have to include the prices if they advertise those drugs to the public. Some companies always will ...
Read Full Story »

Wall Street Has a New Strategy for Legal Marijuana – Whenever That Happens

Posted: May 9, 2019 at 11:01 am

With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged to complement the historically resilient characteristics of alcohol and tobacco. Cannabis stocks ...
Read Full Story »

5 ETFs Targeting a Healthier America

Posted: May 7, 2019 at 10:20 am

Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking — while by no means a guarantee — greatly increase one’s odds of living a long ...
Read Full Story »

Osmotica Pharma Makes Significant Headway With Ptosis Treatment

Posted: May 7, 2019 at 9:45 am

Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) is working to treat ptosis, or droopy eyelid. While this can occur for a number of reasons, Osmotica has made some headway in the treatment ...
Read Full Story »

What Cytokinetics New Study Means for ALS Patients

Posted: May 6, 2019 at 8:59 am

Cytokinetics Inc. (NASDAQ: CYTK) shares took a step back on Monday after the firm announced that its midstage trial for amyotrophic lateral sclerosis (ALS) failed to meet expectations. Specifically, the ...
Read Full Story »

Is Gilead’s Stock and Revenue Free-Fall Finally Bottoming Out?

Posted: May 2, 2019 at 4:53 pm

It's no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes ...
Read Full Story »